MAX is trading down -6.58% during the regular session, around $10.08 versus a $10.79 prior close on Sept. 21. The decline came with no single company-specific headline, pointing to broad-market weakness and profit-taking rather than a discrete catalyst.

GSHD is down -9.75% intraday, sliding to roughly $46.66 from Monday's $51.70 close during regular trading hours. The drop extends a steep multi-session selloff: shares already fell -5.22% on Monday and are off about -14% over the past week.

MMS operates in government services with exposure to federal and state contracts, while TOWN focuses on regional banking in the southeastern U.S. Recent market activity shows MMS maintaining relative stability amid contract renewals and operational efficiencies, contrasting with TOWN ’s sensitivity to interest rate environments and deposit growth trends.

CORT delivered robust Q2 2026 revenue growth of 32% year-over-year and raised full-year guidance amid the launch of its oncology asset. OPK shares have advanced approximately 34% year-to-date, supported by diversified operations and strategic financing moves.

Northwest Biotherapeutics (NWBO) has traded in a narrow range near $0.17 over the past 30 days, with the 30-day percentage change roughly flat at well under 10%. The stock's 52-week range spans roughly $0.14 to $0.34, reflecting the speculative nature of a pre-commercial biotechnology company.

AAR Corp. (AIR) gained +1.08% during the regular session, rising to about $117.51 from a prior close of $116.26. The move extended a multi-day rebound after a fresh bullish note this morning argued the stock's ~27% pullback from its August high was a buying opportunity, citing a $167 price target.

EVER is down -17.26% during regular trading, falling to $18.89 from Friday's $22.83 close. The decline extends a multi-session slide from roughly $24.47 on Sept. 15, with the stock near the lows intraday.

KPLT is trading down -8.84% to $8.04 during the regular session, extending Monday's -7.16% slide from $9.50 to $8.82. Primary catalyst: a Form S-3 shelf registration filed Sept 15, 2026, signaling potential new share issuance and stoking dilution concerns.

QNST is down -14.31% intraday, sliding from a prior close of $17.26 to about $14.79 during the regular session, on elevated volume. The decline extends a sustained slide — the stock was already off roughly -16% over the past month and has shed about -6.6% over the prior week.

The selected price target is $1.00 , a psychological milestone and the level typically required to satisfy Nasdaq's minimum bid price listing rule. Silexion is a clinical-stage biotech advancing SIL204, an RNA interference (RNAi) therapy for KRAS-driven pancreatic cancer, with a Phase 2/3 trial approved in Israel and Germany.

The central question is whether VerifyMe, Inc. (VRME) can climb to a $3 price target , roughly double its most recent closing level. The strongest bullish catalyst is a pending reverse merger with OpenWorld Ltd, a blockchain and real-world asset (RWA) tokenization firm, paired with a planned dual Nasdaq and Figure OPEN on-chain listing.

CLDX is down -17.26% to $31.35 intraday, versus a prior-session close of $37.89. The decline follows a deeper -20%+ premarket drop, driven by a classic "sell-the-news" reaction.

VRME is trading down -32.61% to roughly $0.93 during the regular session, reversing from Monday's close of $1.38. The drop follows Monday's +73% surge (from $0.795 to $1.38) on record volume of roughly 60M shares, driven by merger speculation.

ONON is up +13.14%, rallying from a prior close of $27.32 to about $30.91 in Tuesday's session after starting higher in premarket. The primary catalyst was the company's Investor Day, where it unveiled 2029 targets including at least CHF 5.6 billion in net sales and a 22% adjusted EBITDA margin.

ALL fell -5.15% to about $230.35 during Tuesday's regular session, extending a multi-day slide and touching its lowest level since June. The decline pushed Allstate into the day's top US decliners as investors reacted to mounting catastrophe losses.

NYT dropped about -5.61% to roughly $66.57 intraday, down from a $70.53 prior close, with the slide unfolding during regular trading after a modest premarket gain. Primary catalyst: the U.S. Department of Justice filed a statement of interest backing OpenAI and Microsoft, arguing that training AI on copyrighted works can qualify as fair use in NYT's copyright suit.

LPLA is trading down -7.33% intraday to roughly $307.89, versus a prior close of $332.26, with the drop unfolding during the regular session. The decline was driven primarily by a technical breakdown rather than company-specific news, as the stock broke below its ~$333 weekly support level.

WGS is down about -9.33% intraday during regular trading hours, sliding from a $97.83 prior close to roughly $88.70. The primary catalyst is mounting concern over the CMS laboratory fee schedule proposal, which analysts warned could create confusion across genomics diagnostics names.

VKTX is up +27.53% to $38.40, surging in premarket trading and extending gains into the regular session after a positive VK2735 readout. The primary catalyst: top-line results from the VK2735 maintenance study showed patients retained up to 97% of weight loss on every-other-week dosing and up to 90% on monthly dosing, versus 61% for placebo.

SCHW fell -5.05% during regular market hours, sliding from a $106.88 prior close to roughly $101.48 in morning trading. The move reflects a broad risk-off session across financials, not a company-specific headline.